Colorectal Cancer

1. Front Matter

   Pages i-x

   PDF

2. Molecular Biology of Colon Cancer

   • William M. Grady

   Pages 1-31

3. Chemoprevention of Colorectal Cancer

   • Yu-Ning Wong, Wen-Chi Chang, Margie Clapper, Paul F. Engstrom

   Pages 33-49

4. Colorectal Cancer Screening and Surveillance

   • Arnold J. Markowitz

   Pages 51-68

5. Cytotoxic Chemotherapy for Metastatic Colorectal Cancer

   • M.Wasif Saif, Richard Kim, Edward Chu

   Pages 69-84

6. Integration of Antiangiogenic Strategies Into Colorectal Cancer Treatment

   • John M. Strother, Charles D. Blanke

   Pages 85-98

7. The Role of EGFR Inhibition in Colorectal Cancer

   • Nabeel Shalan, Paulo M. Hoff

   Pages 99-118

8. Second-Line Strategies in the Treatment of Patients With Metastatic Colorectal Cancer

   • Anthony B. El-Khoueiry, Heinz-Josef Lenz

   Pages 119-130

9. Adjuvant Chemotherapy for Colon Cancer

   • Bert H. O’Neil, Hanna Kelly, Michael A. Morse, Richard M. Goldberg

   Pages 131-154

10. Management of Locally Advanced Rectal Cancer

    • Yu Jo Chua, David Cunningham

    Pages 155-189

11. Rationale for Adjuvant and Neoadjuvant Chemotherapy in the Resection of Liver Metastases

    • Axel Grothey, Steven A. Alberts

    Pages 191-203

12. Percutaneous Radiofrequency Ablation in the Management of Patients With Colorectal Cancer

    • Karen Brown

    Pages 205-218

13. Colorectal Cancer Imaging

    • Sean D. Curran, Laurence H. Schwartz

    Pages 219-229

14. Nursing Issues in Colorectal Cancer Chemotherapy

    • Ellen Hollywood, Deborah Semple

    Pages 231-243

15. Pain Management in the Colorectal Cancer Patient

    • Vivek Tim Malhotra

    Pages 245-262

16. Novel Agents and New Paradigms for Colorectal Cancer Beyond EGFR and VEGF

    • Chris Takimoto, Russell Kruzelock

    Pages 263-279

17. Back Matter

    Pages 281-292

    PDF

Management options for patients with colorectal cancer have undergone d- matic changes over the past decade. Whereas at the start of 1996 only one drug, 5-Fluorouracil, was available for the treatment of this disease, a mere 10 yr later, six drugs are licensed for use in colorectal cancer, and others are in the late phases of clinical development. Likewise, surgical and ablative options, as well as an array of supportive medications, have shown substantial progress and undergone a dramatic proliferation over the past decade. With the increased number of therapeutic options from which to choose, the clinician is better able to offer effective therapy to the patient with colorectal cancer. The clinician is challenged, however, to keep up with the rapidly changing landscape and the rapidly emerging data that shape the options for treatment today and tom- row. In this text, leaders in the management of colorectal cancer review the current literature that has led us to where we are today. Critical evaluations of the data are offered, and evidence-based recommendations are made.

• angiogenesis
• cancer
• cancer treatment
• colon
• colorectal cancer
• imaging
• liver
• metastasis
• metastatic disease
• pain
• prevention
• screening

• Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York

  Leonard B. Saltz

Policies and ethics